Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity
Summary Objective Fibroblast growth factor‐21 (FGF21) is a novel endocrine and paracrine regulator of metabolic homeostasis. The aim of our study was to measure its serum concentrations in patients with obesity, obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C), and to assess the...
Gespeichert in:
| Veröffentlicht in: | Clinical endocrinology (Oxford) 2009-09, Vol.71 (3), p.369-375 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 375 |
|---|---|
| container_issue | 3 |
| container_start_page | 369 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 71 |
| creator | Mraz, M. Bartlova, M. Lacinova, Z. Michalsky, D. Kasalicky, M. Haluzikova, D. Matoulek, M. Dostalova, I. Humenanska, V. Haluzik, M. |
| description | Summary
Objective Fibroblast growth factor‐21 (FGF21) is a novel endocrine and paracrine regulator of metabolic homeostasis. The aim of our study was to measure its serum concentrations in patients with obesity, obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C), and to assess the changes of its circulating levels and mRNA expression after dietary and pharmacological interventions.
Design We measured biochemical parameters, serum FGF21, adiponectin, leptin and insulin levels by commercial ELISA and RIA kits, and mRNA expression in the liver, subcutaneous and visceral fat by RT PCR in 26 obese patients, 11 T2DM patients and 32 control subjects. The interventions were acute hyperinsulinaemia during isoglycaemic–hyperinsulinaemic clamp, very low calorie diet (VLCD) and 3 months treatment with PPAR‐α agonist fenofibrate.
Results Baseline serum FGF21 levels were significantly higher in both obese and T2DM patients relative to healthy controls. FGF21 levels in obesity did not significantly differ from T2DM group. Both 3 weeks of VLCD and 3 months of fenofibrate treatment significantly increased FGF21 levels. FGF21 mRNA expression in visceral fat was twofold higher in obesity relative to C group, while it did not differ in subcutaneous fat. VLCD significantly increased FGF21 mRNA expression in subcutaneous fat of obesity. 3‐h hyperinsulinaemia during the clamp increased FGF21 levels in T2DM but not in C group.
Conclusion An increase in FGF21 levels after VLCD and fenofibrate treatment may contribute to positive metabolic effect of these interventions and suggests the possibility of direct positive metabolic effects of FGF21 in humans. |
| doi_str_mv | 10.1111/j.1365-2265.2008.03502.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67608379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67608379</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4662-1fc2f2482eeb8ba195ab1e4d7251ba3781732a7987c6114d1e34ef2d959a42d73</originalsourceid><addsrcrecordid>eNqNkc2O0zAUhSMEYsrAKyBvYJfgn9hOFixQmRmQRoMQg7q0HOdmcEnjYDu0fQ2eGIdUZQne2PL5zj2WT5YhgguS1pttQZjgOaWCFxTjqsCMY1ocHmWrs_A4W2GGcY6FKC-yZyFsMca8wvJpdkFqiamk5Sr79QX8tEPGDQaG6HW0bghIDy2KNoQJEBxGDyGka-Q6pNHgfkKPYGid8XYA5OFh6nV0HnW28a7pdYjowbt9_IY6bZKQU4LsgMY0O0UEtLdJiscREEWt1Q1EWBJdA8HG4_PsSaf7AC9O-2X29frqfv0hv_1083H97jY3pRA0J52hHS0rCtBUjSY11w2BspWUk0YzWRHJqJZ1JY0gpGwJsBI62ta81iVtJbvMXi9zR-9-TBCi2tlgoO_1AG4KSkiBKybrf4IUy5pzwhJYLaDxLgQPnRq93Wl_VASruTi1VXM_au5HzcWpP8WpQ7K-PGVMzQ7av8ZTUwl4dQJ0MLrvvB6MDWeOkoqIBCfu7cLtbQ_H_36AWl_dzafkzxe_DREOZ7_239OHMMnV5u5G8fvy_fXm80ZV7DcV8cUB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20795513</pqid></control><display><type>article</type><title>Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Mraz, M. ; Bartlova, M. ; Lacinova, Z. ; Michalsky, D. ; Kasalicky, M. ; Haluzikova, D. ; Matoulek, M. ; Dostalova, I. ; Humenanska, V. ; Haluzik, M.</creator><creatorcontrib>Mraz, M. ; Bartlova, M. ; Lacinova, Z. ; Michalsky, D. ; Kasalicky, M. ; Haluzikova, D. ; Matoulek, M. ; Dostalova, I. ; Humenanska, V. ; Haluzik, M.</creatorcontrib><description>Summary
Objective Fibroblast growth factor‐21 (FGF21) is a novel endocrine and paracrine regulator of metabolic homeostasis. The aim of our study was to measure its serum concentrations in patients with obesity, obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C), and to assess the changes of its circulating levels and mRNA expression after dietary and pharmacological interventions.
Design We measured biochemical parameters, serum FGF21, adiponectin, leptin and insulin levels by commercial ELISA and RIA kits, and mRNA expression in the liver, subcutaneous and visceral fat by RT PCR in 26 obese patients, 11 T2DM patients and 32 control subjects. The interventions were acute hyperinsulinaemia during isoglycaemic–hyperinsulinaemic clamp, very low calorie diet (VLCD) and 3 months treatment with PPAR‐α agonist fenofibrate.
Results Baseline serum FGF21 levels were significantly higher in both obese and T2DM patients relative to healthy controls. FGF21 levels in obesity did not significantly differ from T2DM group. Both 3 weeks of VLCD and 3 months of fenofibrate treatment significantly increased FGF21 levels. FGF21 mRNA expression in visceral fat was twofold higher in obesity relative to C group, while it did not differ in subcutaneous fat. VLCD significantly increased FGF21 mRNA expression in subcutaneous fat of obesity. 3‐h hyperinsulinaemia during the clamp increased FGF21 levels in T2DM but not in C group.
Conclusion An increase in FGF21 levels after VLCD and fenofibrate treatment may contribute to positive metabolic effect of these interventions and suggests the possibility of direct positive metabolic effects of FGF21 in humans.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1111/j.1365-2265.2008.03502.x</identifier><identifier>PMID: 19702724</identifier><identifier>CODEN: CLECAP</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adiponectin - blood ; Adult ; Biological and medical sciences ; Case-Control Studies ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - diet therapy ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - genetics ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Fenofibrate - therapeutic use ; Fibroblast Growth Factors - blood ; Fibroblast Growth Factors - genetics ; Fundamental and applied biological sciences. Psychology ; Gene Expression - drug effects ; Humans ; Leptin - blood ; Liver - metabolism ; Medical sciences ; Metabolic diseases ; Middle Aged ; Obesity ; Obesity - blood ; Obesity - diet therapy ; Obesity - drug therapy ; Obesity - genetics ; Vertebrates: endocrinology</subject><ispartof>Clinical endocrinology (Oxford), 2009-09, Vol.71 (3), p.369-375</ispartof><rights>2009 Blackwell Publishing Ltd</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4662-1fc2f2482eeb8ba195ab1e4d7251ba3781732a7987c6114d1e34ef2d959a42d73</citedby><cites>FETCH-LOGICAL-c4662-1fc2f2482eeb8ba195ab1e4d7251ba3781732a7987c6114d1e34ef2d959a42d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2265.2008.03502.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2265.2008.03502.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21816197$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19702724$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mraz, M.</creatorcontrib><creatorcontrib>Bartlova, M.</creatorcontrib><creatorcontrib>Lacinova, Z.</creatorcontrib><creatorcontrib>Michalsky, D.</creatorcontrib><creatorcontrib>Kasalicky, M.</creatorcontrib><creatorcontrib>Haluzikova, D.</creatorcontrib><creatorcontrib>Matoulek, M.</creatorcontrib><creatorcontrib>Dostalova, I.</creatorcontrib><creatorcontrib>Humenanska, V.</creatorcontrib><creatorcontrib>Haluzik, M.</creatorcontrib><title>Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description>Summary
Objective Fibroblast growth factor‐21 (FGF21) is a novel endocrine and paracrine regulator of metabolic homeostasis. The aim of our study was to measure its serum concentrations in patients with obesity, obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C), and to assess the changes of its circulating levels and mRNA expression after dietary and pharmacological interventions.
Design We measured biochemical parameters, serum FGF21, adiponectin, leptin and insulin levels by commercial ELISA and RIA kits, and mRNA expression in the liver, subcutaneous and visceral fat by RT PCR in 26 obese patients, 11 T2DM patients and 32 control subjects. The interventions were acute hyperinsulinaemia during isoglycaemic–hyperinsulinaemic clamp, very low calorie diet (VLCD) and 3 months treatment with PPAR‐α agonist fenofibrate.
Results Baseline serum FGF21 levels were significantly higher in both obese and T2DM patients relative to healthy controls. FGF21 levels in obesity did not significantly differ from T2DM group. Both 3 weeks of VLCD and 3 months of fenofibrate treatment significantly increased FGF21 levels. FGF21 mRNA expression in visceral fat was twofold higher in obesity relative to C group, while it did not differ in subcutaneous fat. VLCD significantly increased FGF21 mRNA expression in subcutaneous fat of obesity. 3‐h hyperinsulinaemia during the clamp increased FGF21 levels in T2DM but not in C group.
Conclusion An increase in FGF21 levels after VLCD and fenofibrate treatment may contribute to positive metabolic effect of these interventions and suggests the possibility of direct positive metabolic effects of FGF21 in humans.</description><subject>Adiponectin - blood</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - diet therapy</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Fenofibrate - therapeutic use</subject><subject>Fibroblast Growth Factors - blood</subject><subject>Fibroblast Growth Factors - genetics</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene Expression - drug effects</subject><subject>Humans</subject><subject>Leptin - blood</subject><subject>Liver - metabolism</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Obesity - blood</subject><subject>Obesity - diet therapy</subject><subject>Obesity - drug therapy</subject><subject>Obesity - genetics</subject><subject>Vertebrates: endocrinology</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc2O0zAUhSMEYsrAKyBvYJfgn9hOFixQmRmQRoMQg7q0HOdmcEnjYDu0fQ2eGIdUZQne2PL5zj2WT5YhgguS1pttQZjgOaWCFxTjqsCMY1ocHmWrs_A4W2GGcY6FKC-yZyFsMca8wvJpdkFqiamk5Sr79QX8tEPGDQaG6HW0bghIDy2KNoQJEBxGDyGka-Q6pNHgfkKPYGid8XYA5OFh6nV0HnW28a7pdYjowbt9_IY6bZKQU4LsgMY0O0UEtLdJiscREEWt1Q1EWBJdA8HG4_PsSaf7AC9O-2X29frqfv0hv_1083H97jY3pRA0J52hHS0rCtBUjSY11w2BspWUk0YzWRHJqJZ1JY0gpGwJsBI62ta81iVtJbvMXi9zR-9-TBCi2tlgoO_1AG4KSkiBKybrf4IUy5pzwhJYLaDxLgQPnRq93Wl_VASruTi1VXM_au5HzcWpP8WpQ7K-PGVMzQ7av8ZTUwl4dQJ0MLrvvB6MDWeOkoqIBCfu7cLtbQ_H_36AWl_dzafkzxe_DREOZ7_239OHMMnV5u5G8fvy_fXm80ZV7DcV8cUB</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Mraz, M.</creator><creator>Bartlova, M.</creator><creator>Lacinova, Z.</creator><creator>Michalsky, D.</creator><creator>Kasalicky, M.</creator><creator>Haluzikova, D.</creator><creator>Matoulek, M.</creator><creator>Dostalova, I.</creator><creator>Humenanska, V.</creator><creator>Haluzik, M.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7X8</scope></search><sort><creationdate>200909</creationdate><title>Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity</title><author>Mraz, M. ; Bartlova, M. ; Lacinova, Z. ; Michalsky, D. ; Kasalicky, M. ; Haluzikova, D. ; Matoulek, M. ; Dostalova, I. ; Humenanska, V. ; Haluzik, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4662-1fc2f2482eeb8ba195ab1e4d7251ba3781732a7987c6114d1e34ef2d959a42d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adiponectin - blood</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - diet therapy</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Fenofibrate - therapeutic use</topic><topic>Fibroblast Growth Factors - blood</topic><topic>Fibroblast Growth Factors - genetics</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene Expression - drug effects</topic><topic>Humans</topic><topic>Leptin - blood</topic><topic>Liver - metabolism</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Obesity - blood</topic><topic>Obesity - diet therapy</topic><topic>Obesity - drug therapy</topic><topic>Obesity - genetics</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mraz, M.</creatorcontrib><creatorcontrib>Bartlova, M.</creatorcontrib><creatorcontrib>Lacinova, Z.</creatorcontrib><creatorcontrib>Michalsky, D.</creatorcontrib><creatorcontrib>Kasalicky, M.</creatorcontrib><creatorcontrib>Haluzikova, D.</creatorcontrib><creatorcontrib>Matoulek, M.</creatorcontrib><creatorcontrib>Dostalova, I.</creatorcontrib><creatorcontrib>Humenanska, V.</creatorcontrib><creatorcontrib>Haluzik, M.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mraz, M.</au><au>Bartlova, M.</au><au>Lacinova, Z.</au><au>Michalsky, D.</au><au>Kasalicky, M.</au><au>Haluzikova, D.</au><au>Matoulek, M.</au><au>Dostalova, I.</au><au>Humenanska, V.</au><au>Haluzik, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2009-09</date><risdate>2009</risdate><volume>71</volume><issue>3</issue><spage>369</spage><epage>375</epage><pages>369-375</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><coden>CLECAP</coden><abstract>Summary
Objective Fibroblast growth factor‐21 (FGF21) is a novel endocrine and paracrine regulator of metabolic homeostasis. The aim of our study was to measure its serum concentrations in patients with obesity, obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C), and to assess the changes of its circulating levels and mRNA expression after dietary and pharmacological interventions.
Design We measured biochemical parameters, serum FGF21, adiponectin, leptin and insulin levels by commercial ELISA and RIA kits, and mRNA expression in the liver, subcutaneous and visceral fat by RT PCR in 26 obese patients, 11 T2DM patients and 32 control subjects. The interventions were acute hyperinsulinaemia during isoglycaemic–hyperinsulinaemic clamp, very low calorie diet (VLCD) and 3 months treatment with PPAR‐α agonist fenofibrate.
Results Baseline serum FGF21 levels were significantly higher in both obese and T2DM patients relative to healthy controls. FGF21 levels in obesity did not significantly differ from T2DM group. Both 3 weeks of VLCD and 3 months of fenofibrate treatment significantly increased FGF21 levels. FGF21 mRNA expression in visceral fat was twofold higher in obesity relative to C group, while it did not differ in subcutaneous fat. VLCD significantly increased FGF21 mRNA expression in subcutaneous fat of obesity. 3‐h hyperinsulinaemia during the clamp increased FGF21 levels in T2DM but not in C group.
Conclusion An increase in FGF21 levels after VLCD and fenofibrate treatment may contribute to positive metabolic effect of these interventions and suggests the possibility of direct positive metabolic effects of FGF21 in humans.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19702724</pmid><doi>10.1111/j.1365-2265.2008.03502.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2009-09, Vol.71 (3), p.369-375 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67608379 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adiponectin - blood Adult Biological and medical sciences Case-Control Studies Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diet therapy Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - genetics Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Fenofibrate - therapeutic use Fibroblast Growth Factors - blood Fibroblast Growth Factors - genetics Fundamental and applied biological sciences. Psychology Gene Expression - drug effects Humans Leptin - blood Liver - metabolism Medical sciences Metabolic diseases Middle Aged Obesity Obesity - blood Obesity - diet therapy Obesity - drug therapy Obesity - genetics Vertebrates: endocrinology |
| title | Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T08%3A37%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20concentrations%20and%20tissue%20expression%20of%20a%20novel%20endocrine%20regulator%20fibroblast%20growth%20factor-21%20in%20patients%20with%20type%202%20diabetes%20and%20obesity&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Mraz,%20M.&rft.date=2009-09&rft.volume=71&rft.issue=3&rft.spage=369&rft.epage=375&rft.pages=369-375&rft.issn=0300-0664&rft.eissn=1365-2265&rft.coden=CLECAP&rft_id=info:doi/10.1111/j.1365-2265.2008.03502.x&rft_dat=%3Cproquest_cross%3E67608379%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20795513&rft_id=info:pmid/19702724&rfr_iscdi=true |